Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs TeraWulf Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.46 (market cap $12.58B), while TeraWulf Inc trades at $13.65 (market cap $6.81B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and TeraWulf Inc for 17 Days on average.
| HALO | WULF | |
|---|---|---|
Market Cap | $12.58B | $6.81B |
Volume | 2,179,278 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $115.22 | $28.98 |
52-Week Low | $61.63 | $10.99 |
Typical Hold Time | 0 Days | 17 Days |
Enterprise Value | $14.49B | $9.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TeraWulf (WULF) trades at $13.73, down 4.65% today, amid bearish technical signals despite unanimous analyst optimism. The stock shows severe fundamental strain with negative profit margins (-1,179.94% net income margin) and consecutive earnings misses, though revenue remains stable near $168M. Recent news highlights the company's pivot to AI data center operations, with UBS initiating bullish coverage citing long-term power access advantages.
While analyst consensus points to significant upside (average target $34.92), the stock faces substantial execution risks in its AI transition amid persistent cash burn. Investors must weigh Wall Street's optimistic price targets against the company's current negative profitability and high valuation multiples in a competitive infrastructure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
